Dr. Tse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 646-227-3813
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
Keck School of Medicine of the University of Southern CaliforniaClass of 1997
Certifications & Licensure
NY State Medical License 2002 - 2025
Clinical Trials
- Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2004 Mar 01
- 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2005 May 01
Publications & Presentations
PubMed
- 5 citationsSTimulator of INterferon Genes Agonism Accelerates Anti-tumor Activity in Poorly Immunogenic Tumors.Samanthi A. Perera, Johnny E. Kopinja, Yanhong Ma, Eric S. Muise, Jason Laskey
Molecular Cancer Therapeutics. 2021-11-23 - 6 citationsCharacterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.Robbie L. McLeod, Minilik Angagaw, Toya Nath Baral, Liming Liu, Raymond J. Moniz
Oncotarget. 2018-10-02 - 38 citationsPredictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionJo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima
Cancer Research. 2018-05-15
Press Mentions
CStone Presents Research Data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021October 8th, 2021- CStone Presents Preliminary Results from a Phase Ib Study of the Anti-CTLA-4 Monoclonal Antibody (mAb) CS1002 in Combination with the Anti-PD-1 mAb CS1003 in Patients with Advanced Solid Tumors at ESMO 2021September 19th, 2021
- CStone Received China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0September 15th, 2021
- Join now to see all
Grant Support
- Targeting Cell Cycle Checkpoints In Cancer TherapeuticsNational Cancer Institute2006–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
